Pipeline

Therapies in development

Our research and development teams aim to target the underlying mechanisms of brain disease. We move together towards a singular goal to deliver novel therapies that redefine the standard of care for patients and address the areas in brain disease where we see the greatest need.

Hormonal / neuropeptide signaling


Project	Area
Eptinezumab (anti-CGRP mAb)¹	Migraine prevention²	Filing
Eptinezumab (anti-CGRP mAb)¹	Cluster headache	3
Lu AG09222 (anti-PACAP mAb)³	Migraine prevention²	2
Lu AG13909 (anti-ACTH mAb)⁴	Neurohormonal dysfunctions	1

Circuitry / neuronal biology


Project	Area
Brexpiprazole⁵	PTSD⁶	Filing
Lu AF28996 (D1-D2 agonist)⁷	Parkinson's disease	1
MAGLi program⁸	Neurology	1
Bexicaserin (5HT2C agonist)	Developmental and epileptic encephalopathies	3

Protein aggregation, folding and clearance


Project	Area	Phase 1	Phase 2	Phase 3
Amlenetug (anti α-synuclein mAb)	Synucleinopathies (MSA)				3

Neuroinflammation / Neuroimmunology


Project	Area	Phase 1	Phase 2	Phase 3
Lu AG22515 (CD40L blocker)⁹	Neurology				1

CGRP: Calcitonin gene-related peptide;
Two phase III clinical trials, supporting registration in Asia, including China and Japan: SUNRISE, and SUNSET trials.
PACAP: Pituitary adenylate cyclase activating peptide;
ACTH: Adrenocorticotropic hormone. Two phase Ib trials are currently ongoing in Congenital Adrenal Hyperplasia and Cushing’s Disease. For technical reasons, the latter has been officially categorized as a Phase II trial to adhere to local requirements in Georgia;
Acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors;
Post-traumatic stress disorder;
Dopamine receptor D1 and D2;
MAGLi: Monoacylglycerol lipase (“MAGlipase”) inhibitor;
Ph1b trial ongoing in TED (Thyroid Eye Disease)